Global Opioids Agonist Drugs Market Size By Product (Codeine, Fentanyl, Meperidine, Methadone), By Application (Pain Management, Cough Treatment, Diarrhea Treatment), By Geographic Scope And Forecast

Opioids Agonist Drugs Market Size And Forecast

Opioids Agonist Drugs Market size was valued at USD 18,487.3 Million in 2020 and is projected to reach USD 23,850.2 Million by 2028, growing at a CAGR of 3.24% from 2021 to 2028.

Opioids are generally used for treating pain, and opioid-containing drugs are being misused or are being consumed in overdose when patients follow self-medication. Additionally, the growing prevalence of pain, cough, and diarrhea are other factors driving the growth of the Opioids Agonist Drugs Market. The Global Opioids Agonist Drugs Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Opioids Agonist Drugs Market Definition

Opioids are commonly prescribed for treating pain. The opioid drug class comprises morphine, hydrocodone, oxycodone, heroin, codeine, morphine, fentanyl, and methadone. It is also employed as a cough suppressant and in diarrhea treatment. Opioids can be administered either through pills, liquids, intravenous, transdermal patches, or lozenges. Developed nations in North America and Europe are notorious for the high levels of abuse of this drug. Drugs such as codeine, morphine, fentanyl, and hydrocodone have become a source of addiction, especially among the population owing to the easy availability of the drugs in these regions.

According to the planet Drug Report 2016, a staggering 17.4 million people were suffering from opioid substance abuse in 2014. However, global organizations and regulatory agencies such as the FDA, Centers for Disease Control and Prevention (CDC), and World Health Organization (WHO) are working towards restricting the abuse of opioids by creating awareness and educating prescribers to be cautious while prescribing these drugs. In 2016, the CDC issued guidelines to prescribe opioids, limiting the daily dose of opioids to 90 morphine milligram equivalent (MME).

Global Opioids Agonist Drugs Market Overview

Opioids are generally used for treating pain, and opioid-containing drugs are being misused or are being consumed in overdose when patients follow self-medication. Additionally, the growing prevalence of pain, cough, and diarrhea are other factors driving the growth of the Opioids Agonist Drugs Market. The highly prescribed opioid in the U.S. is hydrocodone.

In recent times, cannabis has emerged as a possible alternative for opioids. Cannabis is legalized in many states in the U.S. as it is considered safer than opioids. The U.S. is a significant consumer of such drugs, legalizing cannabis (marijuana) is expected to have a detrimental impact on Opioids Agonist Drugs Market growth. The Global Opioids Agonist Drugs Market experiences volatility owing to numerous factors such as rampant production of opium and inclination of the masses towards the use of alternate drugs such as cannabis.

Cannabis is now being legalized in most parts of the U.S. the major consumer of cannabis drugs. Moreover, cannabis is that the most cultivated drug crop in the world. Also, consumers in the U.S. find administering cannabis more effective than opioids, which is also impacting the consumption of opioids. Owing to this, Colorado is experiencing a decline in the number of opioid deaths. Cannabis is considered to be a healthy alternative to opioids.

Global Opioids Agonist Drugs MarketSegmentation Analysis

The Global Opioids Agonist Drugs Market is Segmented on the basis of Product, Application, and Geography.

Opioids Agonist Drugs Market, By Product

• Codeine• Fentanyl• Meperidine• Methadone• Others

Based on Product, the market is segmented into Codeine, Fentanyl, Meperidine, Methadone, and Others. The U.S. FDA considers all opioids as a schedule 2 drug; drugs that have high abuse potential. Codeine, fentanyl, meperidine, methadone, morphine, and hydrocodone are the most abused prescription opioid analgesics. The highly prescribed opioid in the U.S. is hydrocodone.

Opioids Agonist Drugs Market, By Application

• Pain Management• Cough Treatment• Diarrhea Treatment

Based on Application, the market is segmented into Pain Management, Cough Treatment, and Diarrhea Treatment. Opioids are commonly used for treating pain and thus this segment drives the market. It is also employed as a cough suppressant and in diarrhea treatment.

Opioids Agonist Drugs Market, By Geography

• North America• Europe• Asia Pacific• Rest of the world

On the basis of regional analysis, the Global Opioids Agonist Drugs Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Contrary to other regions, wherein codeine is assumed to dominate the market globally, North America is anticipated to be essentially driven by sales of hydrocodone opioids. Drug abuse with opioids is characterized by prolonged use or overdosing of the prescribed medication.

Key Players

The “Global Opioids Agonist Drugs Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Purdue Pharma, Titan pharmaceuticals, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc, Sanofi, Sun Pharmaceuticals, Mallinckrodt Pharmaceuticals, Egalet Corporation, Endo Pharmaceuticals Inc., Allergan, Plc, Pfizer Inc. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

Partnerships, Collaborations, and Agreements

• In May 2015, Boehringer Ingelheim and Pharmaxis announce that Boehringer Ingelheim has exercised its option and acquired the clinical development drug PXS4728A, to improve it for the therapies of the liver-related situation NASH and prevent its impacts.

• In October 2017, Titan Pharmaceuticals, Inc. and Opiant Pharmaceuticals, Inc. today announced a collaboration to investigate the advancement of a unique method to the prevention of opioid relapse and overdose in individual people with opioid addiction.

Mergers and Acquisitions

• In November 2020, Titan Pharmaceuticals, Inc. announced today that it has completed its agreement to settle all of its financial obligations with Molteni & S.p.A and Horizon Credit LLC II, as well as its agreement to acquire JT Pharmaceuticals, Inc.’s kappa opioid agonist peptide, JT-09, used in a combined application with Titan’s ProNeura long-term, constant drug delivery technology, for the treatment of acute and chronic pruritus.

Product Launches and Product Expansions

• In May 2016, Titan Pharmaceuticals, Inc. announced that the US Food and Drug Administration has approved Probuphine (buprenorphine) implant, the first result for the maintenance period treatment of opioid reliance in clinically stable subjects receiving 8 mg or less of oral buprenorphine per day.

• in January 2018, In collaboration with Sandoz Inc., a division of Novartis, Pear Therapeutics, Inc. launched reset for patients with opioid use disorder, which is now marketed accessible.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.